These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38149013)

  • 1. Development and validation of a rabbit model of
    Gras E; Vu TTT; Nguyen NTQ; Tran VG; Mao Y; Tran ND; Mai NH; Dong OX; Jung DH; Iorio NLPP; Povoa HCC; Pinheiro MG; Aguiar-Alves F; Weiss WJ; Zheng B; Cheng LI; Stover CK; Sellman BR; DiGiandomenico A; Gibault L; Valour F; Diep BA
    Front Cell Infect Microbiol; 2023; 13():1297281. PubMed ID: 38149013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.
    Nguyen NTQ; Gras E; Tran ND; Nguyen NNY; Lam HTH; Weiss WJ; Doan TNM; Diep BA
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0272420. PubMed ID: 33972247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by
    Farrington N; Dubey V; Johnson A; Horner I; Stevenson A; Unsworth J; Jimenez-Valverde A; Schwartz J; Das S; Hope W; Darlow CA
    mBio; 2024 Feb; 15(2):e0316523. PubMed ID: 38236031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
    Motos A; Yang H; Li Bassi G; Yang M; Meli A; Battaglini D; Cabrera R; Bobi J; Pagliara F; Frigola G; Camprubí-Rimblas M; Fernández-Barat L; Rigol M; Ferrer-Segarra A; Kiarostami K; Martinez D; Nicolau DP; Artigas A; Pelosi P; Vila J; Torres A
    Crit Care; 2023 Feb; 27(1):60. PubMed ID: 36788582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
    [No Abstract]   [Full Text] [Related]  

  • 13. Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome.
    Migiyama Y; Hirosako S; Tokunaga K; Migiyama E; Tashiro T; Sagishima K; Kamohara H; Kinoshita Y; Kohrogi H
    Pulm Pharmacol Ther; 2017 Aug; 45():142-147. PubMed ID: 28450200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
    Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance.
    Farrington N; McEntee L; Johnson A; Unsworth J; Darlow C; Jimenez-Valverde A; Hornik C; Greenberg R; Schwartz J; Das S; Hope W
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0218121. PubMed ID: 35315689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.